Drug Profile
Myeloperoxidase - Exoxemis
Alternative Names: E-101; ZempiaLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Exoxemis
- Class Antibacterials; Antifungals; Antivirals; Glucose oxidases; Peroxidases; Small molecules
- Mechanism of Action Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative infections
- Preclinical Vasculitis
- No development reported Bacterial infections; Mycoses; Viral infections
Most Recent Events
- 28 Jun 2022 Preclinical trials in Vasculitis in USA (unspecified route)
- 01 Jun 2022 Pharmacodynamics data from preclinical studies in Vasculitis presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)
- 08 Sep 2021 Phase-III development is ongoing in Israel (Topical) (Exoxemis website, September 2021)